In Malaysia, ovarian cancer is the 4th most common cancer among women, frequently diagnosed in an advanced stage and with an aggressive clinical course. Despite surgical resection and standard chemotherapy, 70% of the patients may experience disease relapse within 3 years. The introduction of poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitors (PARPi) has marked a crucial step forward in the treatment of these patients. Therefore, the evaluation of BRCA1 and BRCA2 status is encouraged for all patients with advanced non-mucinous epithelial ovarian cancer to guide the therapy decision. The module will take discuss how the treatment paradigm for ovarian cancer has changed in the recent years and how to optimally manage patients using molecular biomarkers.AstraZeneca is leading this digital initiative to focus on educating the gynaecologists on ovarian cancer.Learning ObjectivesThe initiative is based on the theme of "Transforming Ovarian Cancer Care Together" and aims to:
- Increase the awareness of ovarian cancer among HCPs, (especially gynaecologists who are treating ovarian cancer) in order to improve early detection for timely management of ovarian cancer.
- Improve the outcome of ovarian cancer management-to increase the chances of a curative intent of the disease and delay progression for as long as possible.
- Call to action: Gynaecologists are able to discuss BRCA testing with their patients and refer patients for timely diagnosis and management.
There are 6 modules in this course. Participants must successfully complete all 6 modules to obtain 1 CPD point, that will be credited instantly in your MMA CPD account.
About the Presenter
Professor Woo Yin Ling Professor Woo Yin Ling is Professor of Obstetrics and Gynaecology from University of Malaya. She completed her specialist and subspecialty training in gynaecological oncology and postdoctoral research degree in the UK. She returned to Malaysia in 2010 and have since been actively involved in of a number of research programs focusing on screening, prevention and management of gynaecological cancers in the Malaysian setting. Her areas of research interest is in hereditary ovarian cancer and cervical cancer prevention. Prof. Woo is currently the country representative for the Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN), member of the Asia Pacific Economic Consortium (APEC) Cervical Cancer working group and one of the lead investigators for Mainstreaming Genetic Counselling for Genetic Testing of BRCA1 and BRCA2 in Ovarian Cancer Patients in Malaysia (MaGiC Study).
Professor Woo Yin Ling is Professor of Obstetrics and Gynaecology from University of Malaya. She completed her specialist and subspecialty training in gynaecological oncology and postdoctoral research degree in the UK. She returned to Malaysia in 2010 and have since been actively involved in of a number of research programs focusing on screening, prevention and management of gynaecological cancers in the Malaysian setting. Her areas of research interest is in hereditary ovarian cancer and cervical cancer prevention. Prof. Woo is currently the country representative for the Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN), member of the Asia Pacific Economic Consortium (APEC) Cervical Cancer working group and one of the lead investigators for Mainstreaming Genetic Counselling for Genetic Testing of BRCA1 and BRCA2 in Ovarian Cancer Patients in Malaysia (MaGiC Study).